Ternary Glycoprotein Conjugates for Targeted Lysosomal Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current enzyme replacement therapies for lysosomal storage disorders face challenges such as inefficient tissue-specific targeting, immunogenicity, instability of therapeutic proteins within lysosomes, and the need for frequent administration due to proteolytic degradation, which limits their efficacy.
Innovation Solution
Development of ternary conjugates comprising a therapeutic glycoprotein covalently linked with a masking moiety and a targeting moiety through specific linkers, allowing for controlled release of the glycoprotein under lysosomal conditions to enhance targeting and stability, thereby improving bioavailability and activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy is administered to treat lysosomal storage disorders, then the therapeutic protein can replace the deficient enzyme, but the protein suffers from strong immunogenicity and proteolytic degradation that limit its efficacy
Solution Approach 1:
The patent uses a masking moiety (such as polyethylene glycol or other polymers) as an intermediary to coat the therapeutic protein. This masking layer shields the protein from the immune system, reducing immunogenicity and preventing proteolytic degradation. The masking moiety acts as a protective barrier between the therapeutic protein and the harmful immune environment, allowing the protein to circulate longer and reach target tissues effectively.
Solution Approach 2:
The patent modifies the physical and chemical parameters of the therapeutic protein by conjugating it with masking moieties. This changes the protein's size, charge, and hydrophobicity, which collectively reduce immunogenicity and improve stability. The modified parameters allow the protein to evade immune detection and resist degradation, thereby enhancing therapeutic efficacy.
2Reliability
If the oligosaccharide chains are completely removed to improve targeting specificity, then the protein can be more specifically targeted to desired cell types, but the protein loses solubility and intracellular stability
Solution Approach 1:
The patent applies local quality modification by selectively remodeling only specific portions of the oligosaccharide chains rather than complete removal. This allows the protein to retain essential solubility and stability functions provided by the carbohydrate side chains while gaining improved targeting specificity. The masking moiety is locally applied to the protein surface, creating regions with different functional properties.
Solution Approach 2:
The patent creates a composite structure by combining the therapeutic protein with a masking moiety. This composite material integrates the targeting capabilities of the protein with the protective and solubility-enhancing properties of the polymer coating. The resulting conjugate maintains the benefits of both components while mitigating their individual limitations.
3Duration of action of moving object
If the therapeutic protein is administered frequently to maintain efficacy, then the therapeutic effect can be sustained, but the treatment burden and cost increase due to the short half-life from proteolytic degradation
Solution Approach 1:
The masking moiety serves as a protective intermediary that extends the circulation half-life of the therapeutic protein by shielding it from proteolytic enzymes. This extended half-life reduces the frequency of administration required to maintain therapeutic effects, thereby reducing treatment burden and associated costs.
Data Source
AI summary
Methods of making ligand-decorated polymer conjugates of therapeutic glycoproteins are described. Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc., which in turn are decorated with target-specific ligands. In some embodiments, acid-labile linkages in such conjugates or rapidly degradable masking groups allow for the intracellular release of the polymer from the glycoprotein, for example, under conditions found in lysosomes.